The ongoing U.S. government shutdown combined with significant NIH budget cuts poses substantial risks to biomedical innovation, particularly early-stage research and clinical trials. This funding uncertainty threatens to delay scientific breakthroughs, disrupt biotech startups, and cause talent losses, fundamentally impacting the U.S. life sciences ecosystem and its global leadership in biomedical science.